Subsequent to Canon's announcement on March 2, 2018 that it had filed a complaint with the United States International Trade Commission alleging patent infringement by 49 manufacturers, distributors, and resellers on certain laser cartridges used in certain Canon and Hewlett Packard printers, there has been a flurry of activity.
Much of this activity appears to have been initiated by those with the most to lose should Canon fail to prevail in this latest round of litigation. David Gibbons, of Recycling Times Media interviews Ian Elliott to capture his thoughts on the immediate impact in the marketplace and potential outcomes for the ongoing saga.
Transcript:
Well David, yes, I think so! Unless it’s eventually determined otherwise, Canon has valid US patents and clearly believes those patents are being infringed. A patent provides the patentee (along with any of its licensed partners) with a government granted monopoly for the term of the patent. So … yes, this battle is about market share and Canon is entitled to fight that battle.
David, as you know, we’re in the consolidation phase of a mature business and I have a deep interest in how the developments that take place in this final phase are likely to affect the remaining players. It is possible, although probably unlikely, that this round of litigation may turn out to be a defining moment in terms of the battle between new-build and remanufactured, and then ultimately in terms of the subsequent battle for market share between the OEMs and the aftermarket.
It does seem ironic that the ‘278 patent, which was at the heart of the 2014 ‘918 ITC investigation, should have spawned 15+ new patents, nine of which are now asserted against the respondents and which Canon claims protect the technology the aftermarket respondents themselves appear to have introduced in order to resolve the 2014 dispute.
However, at this stage, no one knows whether the new Canon patents are infringed or valid. Hopefully, this is what the ITC investigation will resolve.
The term “clone” is frequently bandied around as a label appearing to discredit any product that isn’t OEM or isn’t remanufactured, but this is wrong because it is only an appropriate label for cartridges that are identical copies of the OEM cartridges.
The aftermarket cartridges utilizing the various gear designs Canon is now complaining about are not direct copies (i.e. clones) of Canon’s current cartridges
However, while they may not be clones, this does not mean they may not infringe certain claims in certain Canon patents. This is what the ITC investigation will be trying to determine.
The manufacturer must accrue for the costs of potential litigation into the cost of its products.
Although manufacturer indemnifications may protect customers from the bulk of the costs of the ITC and district court litigation, there are many hidden costs, including damage to their brands and loss of management time to the distractions of litigation. The costs that are accrued to fight battles in the ITC and district courts should instead be invested in improved attempts to break the cycle of litigation.
This may require additional efforts, both in terms of filing for more patents, and filing patents designed for the future, just as Canon has done with it continuation and divisional patent strategies.
Yes, I would agree this is an accurate definition of remanufactured versus new-build and this, of course, is the crux of the matter. The “new-build” business model has an inherent advantage over remanufactured. They cost less to make, there are virtually no constraints on supply (such as core availability), and, many would argue, they are higher quality, because they’re manufactured from all new parts.
In combination, this represents a serious threat to the legacy remanufacturers of aftermarket cartridges, and potentially, in the longer term could also be a more significant threat to the OEM’s than remanufactured cartridges have ever been. In short David, new-build cartridges represent a disruptive threat to the established order.
Of course, we don’t know what Canon is thinking and what their endgame is apart from knowing they must believe they’re entitled (by way of their government granted monopoly) to a 100% share of the market they’ve protected with their patents.
It seems logical that new-build cartridges represent a bigger threat to OEM market share than remanufactured cartridges do. If this is how Canon views the market, then it’s not surprising their current focus is on the biggest threat.
However, I don’t think this should necessarily be taken as an indication that Canon believes remanufactured products are okay. As we all know, remanufactured cartridges have also been the subject of litigation during the last 20 years and there’s no guarantee they wouldn’t be again in the future.
As you know David, I tend to think in black and white terms of how future events and potential outcomes may develop.
For example;
From an economic perspective, regardless of whether new-build are lower cost than remanufactured cartridges, there are many other factors that come into play that prevent new-build gaining a stronger presence in the marketplace. It’s not just about cost.
From a legal perspective, it would be nice to think the ITC investigation will follow a clear and logical path – a group of top notch lawyers and experts presenting their case for Canon, a comparable group presenting their case for the aftermarket, and the very best qualified minds at the ITC listening to their arguments and deciding the correct legal and technical outcome.
However, although I’m not a legal expert, I suspect the outcome may be a bit more muddled. My gut tells me there’s likely to be a compelling argument that some of Canon’s patents are infringed. But, conversely, there’s also likely to be a compelling argument that Canon’s patents are not valid.
Whether the proceedings run their full course with Canon willing to risk a potential invalidity finding that results in a loss of their patents, or they simply withdraw them from the investigation to prevent this, only time will tell.